Medical Education Library

A supplement to Skin & Allergy News.
This supplement was produced in affiliation with the 32ndHawaii Dermatology SeminarTMand the Cosmetic Dermatology SeminarTM.

•Topic Highlights
•Guest Editors

To view the supplement, click the image above.
Topic Highlights

• Evolution of Fillers Continues at a Rapid Pace
• Development of Fractional Laser Devices: Challenging Clinicians to Keep Pace
• Future Laser May Hit Fat Target
• Extend Cosmetic Offerings to Medical Patients
• 'Mini-Face-Lift' Is in Realm of Cosmetic Surgery
• Injectables Menu Offers Options for Most Patients
• Botanical Products Move to Front of Cosmeceuticals Class
• Bromelain (Pineapple Extract)
• Fractional Laser Side Effect Risk Low, Study Finds
• Fillers Changing Cosmetic Approach
Guest Editors

David J. Goldberg, M.D., J.D.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
Clinical Professor of Dermatology
Director, Laser Research
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham University Law School
New York, New York
Dr. Goldberg has nothing to disclose.

Christopher B. Zachary, M.B.B.S., F.R.C.P.
Professor and Chair
Department of Dermatology
University of California, Irvine
School of Medicine
Irvine, California
Dr. Zachary has nothing to disclose.

Copyright © 2008 by Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was produced in affiliation with the 32ndHawaii Dermatology SeminarTMand the Cosmetic Dermatology SeminarTM.

•Topic Highlights
•Guest Editors

To view the supplement, click the image above.
Topic Highlights

• Evolution of Fillers Continues at a Rapid Pace
• Development of Fractional Laser Devices: Challenging Clinicians to Keep Pace
• Future Laser May Hit Fat Target
• Extend Cosmetic Offerings to Medical Patients
• 'Mini-Face-Lift' Is in Realm of Cosmetic Surgery
• Injectables Menu Offers Options for Most Patients
• Botanical Products Move to Front of Cosmeceuticals Class
• Bromelain (Pineapple Extract)
• Fractional Laser Side Effect Risk Low, Study Finds
• Fillers Changing Cosmetic Approach
Guest Editors

David J. Goldberg, M.D., J.D.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
Clinical Professor of Dermatology
Director, Laser Research
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham University Law School
New York, New York
Dr. Goldberg has nothing to disclose.

Christopher B. Zachary, M.B.B.S., F.R.C.P.
Professor and Chair
Department of Dermatology
University of California, Irvine
School of Medicine
Irvine, California
Dr. Zachary has nothing to disclose.

Copyright © 2008 by Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was produced in affiliation with the 32ndHawaii Dermatology SeminarTMand the Cosmetic Dermatology SeminarTM.

•Topic Highlights
•Guest Editors

To view the supplement, click the image above.
Topic Highlights

• Evolution of Fillers Continues at a Rapid Pace
• Development of Fractional Laser Devices: Challenging Clinicians to Keep Pace
• Future Laser May Hit Fat Target
• Extend Cosmetic Offerings to Medical Patients
• 'Mini-Face-Lift' Is in Realm of Cosmetic Surgery
• Injectables Menu Offers Options for Most Patients
• Botanical Products Move to Front of Cosmeceuticals Class
• Bromelain (Pineapple Extract)
• Fractional Laser Side Effect Risk Low, Study Finds
• Fillers Changing Cosmetic Approach
Guest Editors

David J. Goldberg, M.D., J.D.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
Clinical Professor of Dermatology
Director, Laser Research
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham University Law School
New York, New York
Dr. Goldberg has nothing to disclose.

Christopher B. Zachary, M.B.B.S., F.R.C.P.
Professor and Chair
Department of Dermatology
University of California, Irvine
School of Medicine
Irvine, California
Dr. Zachary has nothing to disclose.

Copyright © 2008 by Elsevier Inc.

A supplement to Skin and Allergy News and supported by SkinMedica.
This supplement is based on a faculty clinical roundtable discussion held September 29, 2007, in San Francisco, California.

Topic Highlights

•Table of Contents
•Faculty/Faculty Disclosure

To view the supplement, click the image above.

• Epidemiology and Pathogenesis

• Treatment Goals and Approaches

• Core Therapy

• Microbial Colonization and Infection

• Adherence Issues

• Topical Steroids: Choices and Issues

• HPA-Axis Suppression

• A New Steroid Option

• Incorporating New Therapy Into Practice

• Summary Comments and Observations

Faculty/Faculty Disclosure

Lawrence F. Eichenfield, MD
Moderator
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego
Chief of Pediatric and Adolescent Dermatology
Rady Children's Hospital
San Diego, California
Dr. Eichenfield has disclosed that he is an investigator for and has received research grants and support from Hill Dermaceuticals, Inc., Novartis Pharmaceuticals Corporation, and Stiefel Laboratories, Inc. He also is a consultant to and on the advisory board of Astellas Pharma Inc., Graceway Pharmaceuticals, LLC, Novartis, Stiefel, and SkinMedica, Inc.

Robert G. Greenberg, MD
Private Practice
Director, East Bay Psoriasis Treatment Center
San Ramon, California
Dr. Greenberg has disclosed that he is a consultant to and on the speaker's bureau for Abbott Laboratories, Amgen Inc., CollaGenex Pharmaceuticals Inc., Dermik Laboratories, Galderma Laboratories, L.P., Genentech, Inc., Medicis Pharmaceutical Corporation, SkinMedica, Stiefel, and Warner Chilcott.

Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Medical Director
DermResearch, PLLC
Louisville, Kentucky
Dr. Kircik has disclosed that he has received research support from, is consultant to, and is on the speaker's bureau for 3M Laboratories, Abbott, Acambis, Allergan Inc., Amgen, Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex, CombiMatrix, Coria Laboratories, Ltd., Dermik, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma, Genentech, GlaxoSmithKline, Healthpoint, Ltd., Intendis, Medicis, Merck Serono, NanoBio Corporation, Novartis, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Stiefel, ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Amy S. Paller, MD
Walter J. Hamlin Professor and Chair
Department of Dermatology
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Dr. Paller has disclosed that she is a consultant to Astellas, Novartis, SkinMedica, and Stiefel.

Rebecca L. Smith, MD
Fort Mill Dermatology, LLC
Fort Mill, South Carolina
Dr. Smith has disclosed that she is a consultant to Coria, SkinMedica, and Stiefel.

Copyright © 2007 Elsevier Inc.

A supplement to Skin and Allergy News and supported by SkinMedica.
This supplement is based on a faculty clinical roundtable discussion held September 29, 2007, in San Francisco, California.

Topic Highlights

•Table of Contents
•Faculty/Faculty Disclosure

To view the supplement, click the image above.

• Epidemiology and Pathogenesis

• Treatment Goals and Approaches

• Core Therapy

• Microbial Colonization and Infection

• Adherence Issues

• Topical Steroids: Choices and Issues

• HPA-Axis Suppression

• A New Steroid Option

• Incorporating New Therapy Into Practice

• Summary Comments and Observations

Faculty/Faculty Disclosure

Lawrence F. Eichenfield, MD
Moderator
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego
Chief of Pediatric and Adolescent Dermatology
Rady Children's Hospital
San Diego, California
Dr. Eichenfield has disclosed that he is an investigator for and has received research grants and support from Hill Dermaceuticals, Inc., Novartis Pharmaceuticals Corporation, and Stiefel Laboratories, Inc. He also is a consultant to and on the advisory board of Astellas Pharma Inc., Graceway Pharmaceuticals, LLC, Novartis, Stiefel, and SkinMedica, Inc.

Robert G. Greenberg, MD
Private Practice
Director, East Bay Psoriasis Treatment Center
San Ramon, California
Dr. Greenberg has disclosed that he is a consultant to and on the speaker's bureau for Abbott Laboratories, Amgen Inc., CollaGenex Pharmaceuticals Inc., Dermik Laboratories, Galderma Laboratories, L.P., Genentech, Inc., Medicis Pharmaceutical Corporation, SkinMedica, Stiefel, and Warner Chilcott.

Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Medical Director
DermResearch, PLLC
Louisville, Kentucky
Dr. Kircik has disclosed that he has received research support from, is consultant to, and is on the speaker's bureau for 3M Laboratories, Abbott, Acambis, Allergan Inc., Amgen, Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex, CombiMatrix, Coria Laboratories, Ltd., Dermik, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma, Genentech, GlaxoSmithKline, Healthpoint, Ltd., Intendis, Medicis, Merck Serono, NanoBio Corporation, Novartis, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Stiefel, ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Amy S. Paller, MD
Walter J. Hamlin Professor and Chair
Department of Dermatology
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Dr. Paller has disclosed that she is a consultant to Astellas, Novartis, SkinMedica, and Stiefel.

Rebecca L. Smith, MD
Fort Mill Dermatology, LLC
Fort Mill, South Carolina
Dr. Smith has disclosed that she is a consultant to Coria, SkinMedica, and Stiefel.

Copyright © 2007 Elsevier Inc.

A supplement to Skin and Allergy News and supported by SkinMedica.
This supplement is based on a faculty clinical roundtable discussion held September 29, 2007, in San Francisco, California.

Topic Highlights

•Table of Contents
•Faculty/Faculty Disclosure

To view the supplement, click the image above.

• Epidemiology and Pathogenesis

• Treatment Goals and Approaches

• Core Therapy

• Microbial Colonization and Infection

• Adherence Issues

• Topical Steroids: Choices and Issues

• HPA-Axis Suppression

• A New Steroid Option

• Incorporating New Therapy Into Practice

• Summary Comments and Observations

Faculty/Faculty Disclosure

Lawrence F. Eichenfield, MD
Moderator
Professor of Pediatrics and Medicine (Dermatology)
University of California, San Diego
Chief of Pediatric and Adolescent Dermatology
Rady Children's Hospital
San Diego, California
Dr. Eichenfield has disclosed that he is an investigator for and has received research grants and support from Hill Dermaceuticals, Inc., Novartis Pharmaceuticals Corporation, and Stiefel Laboratories, Inc. He also is a consultant to and on the advisory board of Astellas Pharma Inc., Graceway Pharmaceuticals, LLC, Novartis, Stiefel, and SkinMedica, Inc.

Robert G. Greenberg, MD
Private Practice
Director, East Bay Psoriasis Treatment Center
San Ramon, California
Dr. Greenberg has disclosed that he is a consultant to and on the speaker's bureau for Abbott Laboratories, Amgen Inc., CollaGenex Pharmaceuticals Inc., Dermik Laboratories, Galderma Laboratories, L.P., Genentech, Inc., Medicis Pharmaceutical Corporation, SkinMedica, Stiefel, and Warner Chilcott.

Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Medical Director
DermResearch, PLLC
Louisville, Kentucky
Dr. Kircik has disclosed that he has received research support from, is consultant to, and is on the speaker's bureau for 3M Laboratories, Abbott, Acambis, Allergan Inc., Amgen, Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex, CombiMatrix, Coria Laboratories, Ltd., Dermik, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma, Genentech, GlaxoSmithKline, Healthpoint, Ltd., Intendis, Medicis, Merck Serono, NanoBio Corporation, Novartis, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Stiefel, ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Amy S. Paller, MD
Walter J. Hamlin Professor and Chair
Department of Dermatology
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Dr. Paller has disclosed that she is a consultant to Astellas, Novartis, SkinMedica, and Stiefel.

Rebecca L. Smith, MD
Fort Mill Dermatology, LLC
Fort Mill, South Carolina
Dr. Smith has disclosed that she is a consultant to Coria, SkinMedica, and Stiefel.

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News and supported by OrthoNeutrogena. The content of this supplement was developed from a roundtable program.

•Faculty/Faculty Disclosures
•Roundtable Participants

To view the supplement, click the image above.

• The Mechanisms of Wound Healing
• The Role of the Macrophage in Wound Healing
• Treatment of Actinic Keratoses and Nonmelanoma Skin Cancer Lesions
• The Use of a Topical Emulsion for Wound Healing
• Radiation Dermatitis
• The Use of a Topical Emulsion for Treatment of Radiation Dermatitis
Faculty/Faculty Disclosures

Joel L. Cohen, MD
Assistant Clinical Professor
Department of Dermatology
University of Colorado
Englewood, Colo.
Dr. Cohen has disclosed that he is a consultant to Johnson & Johnson.

Joseph L. Jorizzo, MD
Professor, Founding and Former Chair
Department of Dermatology
Wake Forest University School of Medicine
Winston-Salem, N.C.
Dr. Jorizzo has nothing to disclose.

Leon H. Kircik, MD
Clinical Professor of Dermatology
Indiana School of Medicine
Medical Director
DermResearch, PLLC
Louisville, Ky.
Dr. Kircik has disclosed that he has received research support from, is consultant to, and is on the speaker's bureau for 3M Pharmaceuticals, Abbott Laboratories, Acambis, Allergan Inc., Amgen Inc., Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex Pharmaceuticals Inc., CombiMatrix, Coria Laboratories, Ltd., Dermik Laboratories, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech, Inc., GlaxoSmithKline, Healthpoint, Ltd. Intendis, Medicis Pharmaceutical Corporation, Merck Serono, NanoBio Corporation, Novartis Pharmaceuticals Corporation, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Inc., Stiefel Laboratories, Inc., ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Roundtable Participants

Linda Carlin, RN, MS, OCn
CJW Medical Center
Richmond Va.

Sharon R. Hymes, MD
University of Texas
Anderson Cancer Center
Houston, Tex.

Tania J. Phillips, MD
Boston University School of Medicine
Boston, Mass.

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News and supported by OrthoNeutrogena. The content of this supplement was developed from a roundtable program.

•Faculty/Faculty Disclosures
•Roundtable Participants

To view the supplement, click the image above.

• The Mechanisms of Wound Healing
• The Role of the Macrophage in Wound Healing
• Treatment of Actinic Keratoses and Nonmelanoma Skin Cancer Lesions
• The Use of a Topical Emulsion for Wound Healing
• Radiation Dermatitis
• The Use of a Topical Emulsion for Treatment of Radiation Dermatitis
Faculty/Faculty Disclosures

Joel L. Cohen, MD
Assistant Clinical Professor
Department of Dermatology
University of Colorado
Englewood, Colo.
Dr. Cohen has disclosed that he is a consultant to Johnson & Johnson.

Joseph L. Jorizzo, MD
Professor, Founding and Former Chair
Department of Dermatology
Wake Forest University School of Medicine
Winston-Salem, N.C.
Dr. Jorizzo has nothing to disclose.

Leon H. Kircik, MD
Clinical Professor of Dermatology
Indiana School of Medicine
Medical Director
DermResearch, PLLC
Louisville, Ky.
Dr. Kircik has disclosed that he has received research support from, is consultant to, and is on the speaker's bureau for 3M Pharmaceuticals, Abbott Laboratories, Acambis, Allergan Inc., Amgen Inc., Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex Pharmaceuticals Inc., CombiMatrix, Coria Laboratories, Ltd., Dermik Laboratories, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech, Inc., GlaxoSmithKline, Healthpoint, Ltd. Intendis, Medicis Pharmaceutical Corporation, Merck Serono, NanoBio Corporation, Novartis Pharmaceuticals Corporation, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Inc., Stiefel Laboratories, Inc., ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Roundtable Participants

Linda Carlin, RN, MS, OCn
CJW Medical Center
Richmond Va.

Sharon R. Hymes, MD
University of Texas
Anderson Cancer Center
Houston, Tex.

Tania J. Phillips, MD
Boston University School of Medicine
Boston, Mass.

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News and supported by OrthoNeutrogena. The content of this supplement was developed from a roundtable program.

•Faculty/Faculty Disclosures
•Roundtable Participants

To view the supplement, click the image above.

• The Mechanisms of Wound Healing
• The Role of the Macrophage in Wound Healing
• Treatment of Actinic Keratoses and Nonmelanoma Skin Cancer Lesions
• The Use of a Topical Emulsion for Wound Healing
• Radiation Dermatitis
• The Use of a Topical Emulsion for Treatment of Radiation Dermatitis
Faculty/Faculty Disclosures

Joel L. Cohen, MD
Assistant Clinical Professor
Department of Dermatology
University of Colorado
Englewood, Colo.
Dr. Cohen has disclosed that he is a consultant to Johnson & Johnson.

Joseph L. Jorizzo, MD
Professor, Founding and Former Chair
Department of Dermatology
Wake Forest University School of Medicine
Winston-Salem, N.C.
Dr. Jorizzo has nothing to disclose.

Leon H. Kircik, MD
Clinical Professor of Dermatology
Indiana School of Medicine
Medical Director
DermResearch, PLLC
Louisville, Ky.
Dr. Kircik has disclosed that he has received research support from, is consultant to, and is on the speaker's bureau for 3M Pharmaceuticals, Abbott Laboratories, Acambis, Allergan Inc., Amgen Inc., Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex Pharmaceuticals Inc., CombiMatrix, Coria Laboratories, Ltd., Dermik Laboratories, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech, Inc., GlaxoSmithKline, Healthpoint, Ltd. Intendis, Medicis Pharmaceutical Corporation, Merck Serono, NanoBio Corporation, Novartis Pharmaceuticals Corporation, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Inc., Stiefel Laboratories, Inc., ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Roundtable Participants

Linda Carlin, RN, MS, OCn
CJW Medical Center
Richmond Va.

Sharon R. Hymes, MD
University of Texas
Anderson Cancer Center
Houston, Tex.

Tania J. Phillips, MD
Boston University School of Medicine
Boston, Mass.

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News and supported by Ferndale Laboratories. The articles in this supplement are based on faculty interviews.

•Topics/Faculty

To view the supplement, click the image above.

Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Medical Director
DermResearch, PLLC
Louisville, Ky
Dr. Kircik has disclosed that he has received research support from, is a consultant to, and is on the speaker's bureau for 3M Pharmaceuticals, Abbott Laboratories, Acambis, Allergan Inc., Amgen Inc., Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex Pharmaceuticals Inc., CombiMatrix, Coria Laboratories, Ltd., Dermik Laboratories, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech, Inc., GlaxoSmithKline, Healthpoint, Ltd., Intendis, Medicis Pharmaceutical Corporation, Merck Serono, NanoBio Corporation, Novartis Pharmaceuticals Corporation, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Inc., Stiefel Laboratories, Inc., ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Poster Review
* Patient Demographics and Baseline Characteristics
* Clinical Assessments
* Safety Evaluation
* Results
* Adverse Events
* Summary by Dr. Kircik

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News and supported by Ferndale Laboratories. The articles in this supplement are based on faculty interviews.

•Topics/Faculty

To view the supplement, click the image above.

Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Medical Director
DermResearch, PLLC
Louisville, Ky
Dr. Kircik has disclosed that he has received research support from, is a consultant to, and is on the speaker's bureau for 3M Pharmaceuticals, Abbott Laboratories, Acambis, Allergan Inc., Amgen Inc., Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex Pharmaceuticals Inc., CombiMatrix, Coria Laboratories, Ltd., Dermik Laboratories, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech, Inc., GlaxoSmithKline, Healthpoint, Ltd., Intendis, Medicis Pharmaceutical Corporation, Merck Serono, NanoBio Corporation, Novartis Pharmaceuticals Corporation, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Inc., Stiefel Laboratories, Inc., ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Poster Review
* Patient Demographics and Baseline Characteristics
* Clinical Assessments
* Safety Evaluation
* Results
* Adverse Events
* Summary by Dr. Kircik

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News and supported by Ferndale Laboratories. The articles in this supplement are based on faculty interviews.

•Topics/Faculty

To view the supplement, click the image above.

Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Medical Director
DermResearch, PLLC
Louisville, Ky
Dr. Kircik has disclosed that he has received research support from, is a consultant to, and is on the speaker's bureau for 3M Pharmaceuticals, Abbott Laboratories, Acambis, Allergan Inc., Amgen Inc., Astellas, Bayer HealthCare Pharmaceuticals, Biogen-Idec, Biolife, LLC, Breckenridge Pharmaceutical, Inc., Centocor, Inc., CollaGenex Pharmaceuticals Inc., CombiMatrix, Coria Laboratories, Ltd., Dermik Laboratories, The Dow Chemical Company, Ferndale Laboratories, Inc., Galderma Laboratories, L.P., Genentech, Inc., GlaxoSmithKline, Healthpoint, Ltd., Intendis, Medicis Pharmaceutical Corporation, Merck Serono, NanoBio Corporation, Novartis Pharmaceuticals Corporation, NUCRYST Pharmaceuticals Corp., OrthoNeutrogena, QLT Inc., Quatrix, SkinMedica, Inc., Stiefel Laboratories, Inc., ToleRx, Inc., Valeant Pharmaceuticals International, and Warner-Chilcott.

Poster Review
* Patient Demographics and Baseline Characteristics
* Clinical Assessments
* Safety Evaluation
* Results
* Adverse Events
* Summary by Dr. Kircik

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News and supported by Johnson & Johnson. The articles in this supplement are based on faculty interviews. This supplement is produced in affiliation with Skin Disease Education Foundation's Women's & Pediatric Dermatology Seminar 2007

A supplement to Skin & Allergy News and supported by Johnson & Johnson. The articles in this supplement are based on faculty interviews. This supplement is produced in affiliation with Skin Disease Education Foundation's Women's & Pediatric Dermatology Seminar 2007

A supplement to Skin & Allergy News and supported by Johnson & Johnson. The articles in this supplement are based on faculty interviews. This supplement is produced in affiliation with Skin Disease Education Foundation's Women's & Pediatric Dermatology Seminar 2007

A supplement to Skin & Allergy News.
The supplement is based on proceedings from the Skin Hydration Summit held on Saturday, March 17, 2007, in New York, New York. This supplement was supported by Unilever.

•Topic Highlights
•Faculty/Faculty Disclosure

To view the supplement, click the image above.

• Foreward

• Introduction

• Stratum Corneum: Physiology and the Role of Hydration

• Cleanser Choice Matters

• Moisturizers
  • Moisturizers With Sun Protection

• Talking to Patients About Skin Care

• Importance of a Skin Care Regimen
  • Acne
  • Atopic Dermatitis
  • Sensitive Skin
  • Additional Skin Conditions

• Patient Compliance: Practical Tips

• Summary

Faculty/Faculty Disclosure

Leslie S. Baumann, MD
Chief, Division of Cosmetic Dermatology
Professor, Clinical Dermatology
University of Miami School of Medicine
Miami, Florida
Dr. Baumann has received funding for clinical grants from Allergan, Inc., Avon Products, Inc., Galderma Laboratories, Medicis Pharmaceuticals Corporation, Stiefel Laboratories, and Unilever PLC.

Diane S. Berson, MD, FAAD
Assistant Professor, Department of Dermatology
Weill Medical College of Cornell University
Assistant Attending Dermatologist
New York-Presbyterian Hospital
New York, New York
Dr. Berson is a consultant to Kao Brands and OrthoNeutrogena. She has received funding for clinical grants from CollaGenex, Inc., DUSA Pharmaceuticals, Inc., Galderma Laboratories, Medicis Pharmaceuticals Corporation, and Stiefel Laboratories.

Fran E. Cook-Bolden, MD
Clinical Assistant Professor, Dermatology
College of Physicians and Surgeons
Columbia University
Attending Physician, Dermatology
St. Luke's-Roosevelt Hospital Center
New York, New York
Dr. Cook-Bolden has nothing to disclose.

David J. Goldberg, MD, JD
Clinical Professor, Dermatology
Director, Laser Research
Mount Sinai School of Medicine
New York, New York
Clinical Professor, Dermatology
Chief, Dermatologic Surgery
University of Medicine and Dentistry of New Jersey-New Jersey Medical School
Newark, New Jersey
Dr. Goldberg has nothing to disclose.

Jennifer H. Goldwasser, MD
Clinical Assistant Professor, Dermatology
New York Medical College
Valhalla, New York
Assistant Attending Physician, Dermatology
White Plains Hospital Center
White Plains, New York
Dr. Goldwasser has nothing to disclose.

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News.
The supplement is based on proceedings from the Skin Hydration Summit held on Saturday, March 17, 2007, in New York, New York. This supplement was supported by Unilever.

•Topic Highlights
•Faculty/Faculty Disclosure

To view the supplement, click the image above.

• Foreward

• Introduction

• Stratum Corneum: Physiology and the Role of Hydration

• Cleanser Choice Matters

• Moisturizers
  • Moisturizers With Sun Protection

• Talking to Patients About Skin Care

• Importance of a Skin Care Regimen
  • Acne
  • Atopic Dermatitis
  • Sensitive Skin
  • Additional Skin Conditions

• Patient Compliance: Practical Tips

• Summary

Faculty/Faculty Disclosure

Leslie S. Baumann, MD
Chief, Division of Cosmetic Dermatology
Professor, Clinical Dermatology
University of Miami School of Medicine
Miami, Florida
Dr. Baumann has received funding for clinical grants from Allergan, Inc., Avon Products, Inc., Galderma Laboratories, Medicis Pharmaceuticals Corporation, Stiefel Laboratories, and Unilever PLC.

Diane S. Berson, MD, FAAD
Assistant Professor, Department of Dermatology
Weill Medical College of Cornell University
Assistant Attending Dermatologist
New York-Presbyterian Hospital
New York, New York
Dr. Berson is a consultant to Kao Brands and OrthoNeutrogena. She has received funding for clinical grants from CollaGenex, Inc., DUSA Pharmaceuticals, Inc., Galderma Laboratories, Medicis Pharmaceuticals Corporation, and Stiefel Laboratories.

Fran E. Cook-Bolden, MD
Clinical Assistant Professor, Dermatology
College of Physicians and Surgeons
Columbia University
Attending Physician, Dermatology
St. Luke's-Roosevelt Hospital Center
New York, New York
Dr. Cook-Bolden has nothing to disclose.

David J. Goldberg, MD, JD
Clinical Professor, Dermatology
Director, Laser Research
Mount Sinai School of Medicine
New York, New York
Clinical Professor, Dermatology
Chief, Dermatologic Surgery
University of Medicine and Dentistry of New Jersey-New Jersey Medical School
Newark, New Jersey
Dr. Goldberg has nothing to disclose.

Jennifer H. Goldwasser, MD
Clinical Assistant Professor, Dermatology
New York Medical College
Valhalla, New York
Assistant Attending Physician, Dermatology
White Plains Hospital Center
White Plains, New York
Dr. Goldwasser has nothing to disclose.

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News.
The supplement is based on proceedings from the Skin Hydration Summit held on Saturday, March 17, 2007, in New York, New York. This supplement was supported by Unilever.

•Topic Highlights
•Faculty/Faculty Disclosure

To view the supplement, click the image above.

• Foreward

• Introduction

• Stratum Corneum: Physiology and the Role of Hydration

• Cleanser Choice Matters

• Moisturizers
  • Moisturizers With Sun Protection

• Talking to Patients About Skin Care

• Importance of a Skin Care Regimen
  • Acne
  • Atopic Dermatitis
  • Sensitive Skin
  • Additional Skin Conditions

• Patient Compliance: Practical Tips

• Summary

Faculty/Faculty Disclosure

Leslie S. Baumann, MD
Chief, Division of Cosmetic Dermatology
Professor, Clinical Dermatology
University of Miami School of Medicine
Miami, Florida
Dr. Baumann has received funding for clinical grants from Allergan, Inc., Avon Products, Inc., Galderma Laboratories, Medicis Pharmaceuticals Corporation, Stiefel Laboratories, and Unilever PLC.

Diane S. Berson, MD, FAAD
Assistant Professor, Department of Dermatology
Weill Medical College of Cornell University
Assistant Attending Dermatologist
New York-Presbyterian Hospital
New York, New York
Dr. Berson is a consultant to Kao Brands and OrthoNeutrogena. She has received funding for clinical grants from CollaGenex, Inc., DUSA Pharmaceuticals, Inc., Galderma Laboratories, Medicis Pharmaceuticals Corporation, and Stiefel Laboratories.

Fran E. Cook-Bolden, MD
Clinical Assistant Professor, Dermatology
College of Physicians and Surgeons
Columbia University
Attending Physician, Dermatology
St. Luke's-Roosevelt Hospital Center
New York, New York
Dr. Cook-Bolden has nothing to disclose.

David J. Goldberg, MD, JD
Clinical Professor, Dermatology
Director, Laser Research
Mount Sinai School of Medicine
New York, New York
Clinical Professor, Dermatology
Chief, Dermatologic Surgery
University of Medicine and Dentistry of New Jersey-New Jersey Medical School
Newark, New Jersey
Dr. Goldberg has nothing to disclose.

Jennifer H. Goldwasser, MD
Clinical Assistant Professor, Dermatology
New York Medical College
Valhalla, New York
Assistant Attending Physician, Dermatology
White Plains Hospital Center
White Plains, New York
Dr. Goldwasser has nothing to disclose.

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was supported by PharmaDerm®
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 31st Annual Hawaii Dermatology Seminar, a continuing medical education program, on March 6, 2007, in Maui, Hawaii.

•Topic Highlights/Faculty
•Target Audience

To view the supplement, click the image above.

Topical Steroids in Pediatric Atopic Dermatitis
Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Indianapolis, Ind.
Medical Director
Derm Research, PLLC
Louisville, Ky.
Dr. Kircik has received funding for clinical grants from and is a consultant to Abbott Laboratories, Acambis, Allergan, Inc., Amgen Inc., Astellas Pharma US (Fujisawa), Berlex, Inc., Biogen-Idec, Inc., Breckenridge Pharmaceutical, Centocor, Inc., CollaGenex, Inc., CombiMatrix Corporation, Connetics Corporation, Coria Laboratories, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Galderma Laboratories, L.P., Genentech Inc., GlaxoSmith Kline, Healthpoint Ltd., Intendis GmbH, 3M Pharmaceuticals, Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceuticals, OrthoNeutrogena Corporation, PharmaDerm, QLT Inc., QuatRx Pharmaceuticals, Serono S.A., SkinMedica, Inc., and Stiefel Laboratories, Inc. Dr. Kircik has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.

Topical Antifungals: An Update
Douglas W. Kress, MD
Chief of Pediatric Dermatology
Children's Hospital of Pittsburgh
Pittsburgh, Penn.
Dr. Kress has received honoraria, grant funding, and has served on the advisory board for PharmaDerm. Dr. Kress has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.
Target Audience

This activity is intended for health care professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with atopic dermatitis.

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was supported by PharmaDerm®
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 31st Annual Hawaii Dermatology Seminar, a continuing medical education program, on March 6, 2007, in Maui, Hawaii.

•Topic Highlights/Faculty
•Target Audience

To view the supplement, click the image above.

Topical Steroids in Pediatric Atopic Dermatitis
Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Indianapolis, Ind.
Medical Director
Derm Research, PLLC
Louisville, Ky.
Dr. Kircik has received funding for clinical grants from and is a consultant to Abbott Laboratories, Acambis, Allergan, Inc., Amgen Inc., Astellas Pharma US (Fujisawa), Berlex, Inc., Biogen-Idec, Inc., Breckenridge Pharmaceutical, Centocor, Inc., CollaGenex, Inc., CombiMatrix Corporation, Connetics Corporation, Coria Laboratories, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Galderma Laboratories, L.P., Genentech Inc., GlaxoSmith Kline, Healthpoint Ltd., Intendis GmbH, 3M Pharmaceuticals, Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceuticals, OrthoNeutrogena Corporation, PharmaDerm, QLT Inc., QuatRx Pharmaceuticals, Serono S.A., SkinMedica, Inc., and Stiefel Laboratories, Inc. Dr. Kircik has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.

Topical Antifungals: An Update
Douglas W. Kress, MD
Chief of Pediatric Dermatology
Children's Hospital of Pittsburgh
Pittsburgh, Penn.
Dr. Kress has received honoraria, grant funding, and has served on the advisory board for PharmaDerm. Dr. Kress has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.
Target Audience

This activity is intended for health care professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with atopic dermatitis.

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was supported by PharmaDerm®
The articles in this supplement are based on presentations made during Skin Disease Education Foundation's 31st Annual Hawaii Dermatology Seminar, a continuing medical education program, on March 6, 2007, in Maui, Hawaii.

•Topic Highlights/Faculty
•Target Audience

To view the supplement, click the image above.

Topical Steroids in Pediatric Atopic Dermatitis
Leon H. Kircik, MD
Associate Clinical Professor of Dermatology
Indiana University Medical Center
Indianapolis, Ind.
Medical Director
Derm Research, PLLC
Louisville, Ky.
Dr. Kircik has received funding for clinical grants from and is a consultant to Abbott Laboratories, Acambis, Allergan, Inc., Amgen Inc., Astellas Pharma US (Fujisawa), Berlex, Inc., Biogen-Idec, Inc., Breckenridge Pharmaceutical, Centocor, Inc., CollaGenex, Inc., CombiMatrix Corporation, Connetics Corporation, Coria Laboratories, Dermik Laboratories, Dowpharma, Ferndale Laboratories, Galderma Laboratories, L.P., Genentech Inc., GlaxoSmith Kline, Healthpoint Ltd., Intendis GmbH, 3M Pharmaceuticals, Medicis Pharmaceutical Corporation, Novartis Pharmaceuticals Corporation, Nucryst Pharmaceuticals, OrthoNeutrogena Corporation, PharmaDerm, QLT Inc., QuatRx Pharmaceuticals, Serono S.A., SkinMedica, Inc., and Stiefel Laboratories, Inc. Dr. Kircik has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.

Topical Antifungals: An Update
Douglas W. Kress, MD
Chief of Pediatric Dermatology
Children's Hospital of Pittsburgh
Pittsburgh, Penn.
Dr. Kress has received honoraria, grant funding, and has served on the advisory board for PharmaDerm. Dr. Kress has indicated that he will not include reference to off-label/investigational uses of drugs or devices in his article.
Target Audience

This activity is intended for health care professionals, including dermatologists and pediatricians, who are involved in the treatment of patients with atopic dermatitis.

Copyright © 2007 Elsevier Inc.

A supplement to Skin & Allergy News and supported by Warner Chilcott.
This supplement to Skin & Allergy News is based on an expert roundtable as well as a presentation made at Skin Disease Education Foundation's 7th Annual Las Vegas Dermatology Seminar, a continuing medical education program, held November 10-12, 2006 in Las Vegas, Nevada.

•Topics
•Faculty/Faculty Disclosure Statement

To view the supplement, click the image above.

• Introduction
• Current Topical Therapies for Psoriasis
• Efficacy of a Novel 2-Compound Ointment
• Safety Profile of a Novel 2-Compound Ointment
• Role of a 2-Compound Ointment in the Treatment Armamentarium for Psoriasis Vulgaris

Faculty/Faculty Disclosure Statement

Craig Leonardi, MD—Chair
Associate Clinical Professor of Dermatology
Saint Louis University
St. Louis, Missouri
Dr. Leonardi is a consultant for Abbott Laboratories, Amgen, Inc., Centocor, Inc., and Genentech, Inc. He has been an investigator for Abbott, Allergan, Inc., Altana, Inc., Amgen, Astellas Pharma US, Bristol-Myers Squibb, Centocor, CombinatoRx, Galderma Laboratories, L.P., Genentech, Novartis Pharmaceuticals, RTL, Schering-Plough Corporation, 3M Pharmaceuticals, and Vitae Pharmaceuticals. He is on the speakers' bureau for Abbott, Amgen, Centocor, Genentech, and Warner Chilcott (US), Inc.

Jerry Bagel, MD
Director of the Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey
Clinical Assistant Professor of Dermatology
College of Physicians and Surgeons at Columbia University
New York, New York
Dr. Bagel speaks for Abbott, Amgen, Astellas, Genentech, Novartis, and Warner Chilcott. He is an investigator for Amgen, Astellas, Centocor, and Galderma.

Mark Lebwohl, MD
Professor and Chairman
Department of Dermatology
Mount Sinai School of Medicine
New York, New York
Dr. Lebwohl is a consultant for or has pending consulting agreements for Abbott, Amgen, Astellas, Bristol-Myers Squibb, Centocor, Connetics Pharmaceuticals, Galderma, Genentech, Novartis, Pfizer, Inc., 3M, and Warner Chilcott. In the last 12 months, he has served as a speaker for Abbott, Amgen, Astellas, Centocor, Chester Valley, Connetics, Galderma, Genentech, Novartis, PharmaDerm, 3M, and Warner Chilcott.

Linda Stein Gold, MD
Director of Dermatology Clinical Research
Henry Ford Health System
Detroit, Michigan
Dr. Gold is a principal investigator, consultant, and member of the speakers' bureau for Connetics, Galderma, and Warner Chilcott. She is a member of the speakers' bureau and a consultant for Genentech, and she is also a principal investigator for Astellas.

The participants discuss using the 2-compound ointment beyond the 4 weeks indicated by the product labeling.

A supplement to Skin & Allergy News and supported by Warner Chilcott.
This supplement to Skin & Allergy News is based on an expert roundtable as well as a presentation made at Skin Disease Education Foundation's 7th Annual Las Vegas Dermatology Seminar, a continuing medical education program, held November 10-12, 2006 in Las Vegas, Nevada.

•Topics
•Faculty/Faculty Disclosure Statement

To view the supplement, click the image above.

• Introduction
• Current Topical Therapies for Psoriasis
• Efficacy of a Novel 2-Compound Ointment
• Safety Profile of a Novel 2-Compound Ointment
• Role of a 2-Compound Ointment in the Treatment Armamentarium for Psoriasis Vulgaris

Faculty/Faculty Disclosure Statement

Craig Leonardi, MD—Chair
Associate Clinical Professor of Dermatology
Saint Louis University
St. Louis, Missouri
Dr. Leonardi is a consultant for Abbott Laboratories, Amgen, Inc., Centocor, Inc., and Genentech, Inc. He has been an investigator for Abbott, Allergan, Inc., Altana, Inc., Amgen, Astellas Pharma US, Bristol-Myers Squibb, Centocor, CombinatoRx, Galderma Laboratories, L.P., Genentech, Novartis Pharmaceuticals, RTL, Schering-Plough Corporation, 3M Pharmaceuticals, and Vitae Pharmaceuticals. He is on the speakers' bureau for Abbott, Amgen, Centocor, Genentech, and Warner Chilcott (US), Inc.

Jerry Bagel, MD
Director of the Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey
Clinical Assistant Professor of Dermatology
College of Physicians and Surgeons at Columbia University
New York, New York
Dr. Bagel speaks for Abbott, Amgen, Astellas, Genentech, Novartis, and Warner Chilcott. He is an investigator for Amgen, Astellas, Centocor, and Galderma.

Mark Lebwohl, MD
Professor and Chairman
Department of Dermatology
Mount Sinai School of Medicine
New York, New York
Dr. Lebwohl is a consultant for or has pending consulting agreements for Abbott, Amgen, Astellas, Bristol-Myers Squibb, Centocor, Connetics Pharmaceuticals, Galderma, Genentech, Novartis, Pfizer, Inc., 3M, and Warner Chilcott. In the last 12 months, he has served as a speaker for Abbott, Amgen, Astellas, Centocor, Chester Valley, Connetics, Galderma, Genentech, Novartis, PharmaDerm, 3M, and Warner Chilcott.

Linda Stein Gold, MD
Director of Dermatology Clinical Research
Henry Ford Health System
Detroit, Michigan
Dr. Gold is a principal investigator, consultant, and member of the speakers' bureau for Connetics, Galderma, and Warner Chilcott. She is a member of the speakers' bureau and a consultant for Genentech, and she is also a principal investigator for Astellas.

The participants discuss using the 2-compound ointment beyond the 4 weeks indicated by the product labeling.

A supplement to Skin & Allergy News and supported by Warner Chilcott.
This supplement to Skin & Allergy News is based on an expert roundtable as well as a presentation made at Skin Disease Education Foundation's 7th Annual Las Vegas Dermatology Seminar, a continuing medical education program, held November 10-12, 2006 in Las Vegas, Nevada.

•Topics
•Faculty/Faculty Disclosure Statement

To view the supplement, click the image above.

• Introduction
• Current Topical Therapies for Psoriasis
• Efficacy of a Novel 2-Compound Ointment
• Safety Profile of a Novel 2-Compound Ointment
• Role of a 2-Compound Ointment in the Treatment Armamentarium for Psoriasis Vulgaris

Faculty/Faculty Disclosure Statement

Craig Leonardi, MD—Chair
Associate Clinical Professor of Dermatology
Saint Louis University
St. Louis, Missouri
Dr. Leonardi is a consultant for Abbott Laboratories, Amgen, Inc., Centocor, Inc., and Genentech, Inc. He has been an investigator for Abbott, Allergan, Inc., Altana, Inc., Amgen, Astellas Pharma US, Bristol-Myers Squibb, Centocor, CombinatoRx, Galderma Laboratories, L.P., Genentech, Novartis Pharmaceuticals, RTL, Schering-Plough Corporation, 3M Pharmaceuticals, and Vitae Pharmaceuticals. He is on the speakers' bureau for Abbott, Amgen, Centocor, Genentech, and Warner Chilcott (US), Inc.

Jerry Bagel, MD
Director of the Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey
Clinical Assistant Professor of Dermatology
College of Physicians and Surgeons at Columbia University
New York, New York
Dr. Bagel speaks for Abbott, Amgen, Astellas, Genentech, Novartis, and Warner Chilcott. He is an investigator for Amgen, Astellas, Centocor, and Galderma.

Mark Lebwohl, MD
Professor and Chairman
Department of Dermatology
Mount Sinai School of Medicine
New York, New York
Dr. Lebwohl is a consultant for or has pending consulting agreements for Abbott, Amgen, Astellas, Bristol-Myers Squibb, Centocor, Connetics Pharmaceuticals, Galderma, Genentech, Novartis, Pfizer, Inc., 3M, and Warner Chilcott. In the last 12 months, he has served as a speaker for Abbott, Amgen, Astellas, Centocor, Chester Valley, Connetics, Galderma, Genentech, Novartis, PharmaDerm, 3M, and Warner Chilcott.

Linda Stein Gold, MD
Director of Dermatology Clinical Research
Henry Ford Health System
Detroit, Michigan
Dr. Gold is a principal investigator, consultant, and member of the speakers' bureau for Connetics, Galderma, and Warner Chilcott. She is a member of the speakers' bureau and a consultant for Genentech, and she is also a principal investigator for Astellas.

The participants discuss using the 2-compound ointment beyond the 4 weeks indicated by the product labeling.

A supplement to Skin & Allergy News.
This supplement was produced in affiliation with the 31st Hawaii Dermatology Seminar and the Cosmetic Dermatology Seminar.

•Topic Highlights
•Guest Editors

To view the supplement, click the image above.

• Advances in Cellulite Treatment and Dermatologic Use of Mesotherapy
• Fractionated Delivery of Laser Energy Continues Evolution, Clinical Expansion
• Photodynamic Therapy's Efficacy Draws Strong Testimonials
• Proper Technique Delivers Optimal Filler Effects
• Tailor Cosmesis to Patients of Color
• Patience, Patients: Some Laser Results Are Subtle
• Glycerol
• Patient Expectations Play a Role in Botox Effects
• Small Anesthetic Changes Can Have Big Impact on Blepharoplasty Results

Guest Editors

David J. Goldberg, M.D., J.D.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
Clinical Professor of Dermatology
Director, Laser Research
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham University Law School
New York, N.Y.
Dr. Goldberg has received clinical grants from Alma Lasers Inc. He is a consultant to Photo Therapeutics Inc., and Ultrashape Inc. He discusses the off-label use of cellulite treatments.

Christopher B. Zachary, M.B.B.S., F.R.C.P.
Professor and Chair
Department of Dermatology
University of California, Irvine
School of Medicine
Dr. Zachary has nothing to disclose.

Copyright © 2006 Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was produced in affiliation with the 31st Hawaii Dermatology Seminar and the Cosmetic Dermatology Seminar.

•Topic Highlights
•Guest Editors

To view the supplement, click the image above.

• Advances in Cellulite Treatment and Dermatologic Use of Mesotherapy
• Fractionated Delivery of Laser Energy Continues Evolution, Clinical Expansion
• Photodynamic Therapy's Efficacy Draws Strong Testimonials
• Proper Technique Delivers Optimal Filler Effects
• Tailor Cosmesis to Patients of Color
• Patience, Patients: Some Laser Results Are Subtle
• Glycerol
• Patient Expectations Play a Role in Botox Effects
• Small Anesthetic Changes Can Have Big Impact on Blepharoplasty Results

Guest Editors

David J. Goldberg, M.D., J.D.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
Clinical Professor of Dermatology
Director, Laser Research
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham University Law School
New York, N.Y.
Dr. Goldberg has received clinical grants from Alma Lasers Inc. He is a consultant to Photo Therapeutics Inc., and Ultrashape Inc. He discusses the off-label use of cellulite treatments.

Christopher B. Zachary, M.B.B.S., F.R.C.P.
Professor and Chair
Department of Dermatology
University of California, Irvine
School of Medicine
Dr. Zachary has nothing to disclose.

Copyright © 2006 Elsevier Inc.

A supplement to Skin & Allergy News.
This supplement was produced in affiliation with the 31st Hawaii Dermatology Seminar and the Cosmetic Dermatology Seminar.

•Topic Highlights
•Guest Editors

To view the supplement, click the image above.

• Advances in Cellulite Treatment and Dermatologic Use of Mesotherapy
• Fractionated Delivery of Laser Energy Continues Evolution, Clinical Expansion
• Photodynamic Therapy's Efficacy Draws Strong Testimonials
• Proper Technique Delivers Optimal Filler Effects
• Tailor Cosmesis to Patients of Color
• Patience, Patients: Some Laser Results Are Subtle
• Glycerol
• Patient Expectations Play a Role in Botox Effects
• Small Anesthetic Changes Can Have Big Impact on Blepharoplasty Results

Guest Editors

David J. Goldberg, M.D., J.D.
Director, Skin Laser & Surgery Specialists of New York/New Jersey
Clinical Professor of Dermatology
Director, Laser Research
Mount Sinai School of Medicine
Adjunct Professor of Law
Fordham University Law School
New York, N.Y.
Dr. Goldberg has received clinical grants from Alma Lasers Inc. He is a consultant to Photo Therapeutics Inc., and Ultrashape Inc. He discusses the off-label use of cellulite treatments.

Christopher B. Zachary, M.B.B.S., F.R.C.P.
Professor and Chair
Department of Dermatology
University of California, Irvine
School of Medicine
Dr. Zachary has nothing to disclose.

Copyright © 2006 Elsevier Inc.